SG11201804496UA - Recombinant zika vaccines - Google Patents

Recombinant zika vaccines

Info

Publication number
SG11201804496UA
SG11201804496UA SG11201804496UA SG11201804496UA SG11201804496UA SG 11201804496U A SG11201804496U A SG 11201804496UA SG 11201804496U A SG11201804496U A SG 11201804496UA SG 11201804496U A SG11201804496U A SG 11201804496UA SG 11201804496U A SG11201804496U A SG 11201804496UA
Authority
SG
Singapore
Prior art keywords
international
zika virus
recombinant
vienna
pct
Prior art date
Application number
SG11201804496UA
Inventor
Erich Tauber
Sabrina Schrauf
Matthias Müllner
Katrin Ramsauer
Angelika Irmler
Patrick Csar
Original Assignee
Themis Bioscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Themis Bioscience Gmbh filed Critical Themis Bioscience Gmbh
Publication of SG11201804496UA publication Critical patent/SG11201804496UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/282—Porous sorbents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau (43) International Publication Date ..... ...sr ,„,„1 29 June 2017(29.06.2017) WIPO I PCT ID Hit (10) 111111111111111111Ill WO International IIIII 2017/109222 Publication 1111111111111111111111111111111 Al Number RIO IIII IIIIIIII (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 39/12 (2006.01) C07K 14/005 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, PCT/EP2016/082659 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 23 December 2016 (23.12.2016) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 15202480.8 23 December 2015 (23.12.2015) EP kind of regional protection available): ARIPO (BW, GH, 16162688.2 29 March 2016 (29.03.2016) EP GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: THEMIS BIOSCIENCE GMBH [AT/AT]; TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Muthgasse 11/2, 1190 Vienna (AT). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors: TAUBER, Erich; Tullner Strasse 16, 3426 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Muckendorf (AT). SCHRAUF, Sabrina; Weingartenweg GW, KM, ML, MR, NE, SN, TD, TG). 1, 7072 Morbisch Am See (AT). MULLNER, Matthias; RehstraBe 9, 3441 Pixendorf (AT). RAMSAUER, Katrin; Declarations under Rule 4.17: Loimerweg 10A/2, 1220 Vienna (AT). IRMLER, An- of inventorship (Rule 4.17(iv)) gelika; Carabelligasse 8, 1210 Vienna (AT). CSAR, Published: Patrick; Rieslinggasse 10, 3433 Konigstetten (AT). (74) Agent: EISENFUHR SPEISER PATENTANWALTE — with international search report (Art 21 ( 3 )) RECHTSANWALTE PARTGMBH; P.O. Box 31 02 60, _ with sequence listing part of description (Rule 5.2(a)) 80102 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, Il .4t N N (54) Title: RECOMBINANT ZIKA VACCINES CT\ 0 (57) : The present invention relates to the provision of immunogenic or vaccine compositions comprising at least one 11 ---- re- combinant Zika virus antigen, wherein the at least one recombinant Zika virus antigen is encoded by at least one nucleic acid se - L -- quence encoding at least one E-protein of a Zika virus or a functional fragment thereof. Further provided are nucleic acid molecules ::::, and a recombinant chimeric virus encoding and/or comprising selected antigens from a Zika virus, which are suitable as vaccine ei compositions. Preferably, the sequences encoding at least one Zika virus antigens suitable for eliciting an immune response are oper- 0 ably linked to a non-flavivirus derived vector backbone. Further provided are methods for purifying the recombinant chimeric virus particles or the immunogenic composition. Finally, there is provided an immunogenic/vaccinecomposition for use in a method of preventing or treating a Zika virus disease.
SG11201804496UA 2015-12-23 2016-12-23 Recombinant zika vaccines SG11201804496UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15202480.8A EP3184119A1 (en) 2015-12-23 2015-12-23 Chromatography based purification strategies for measles scaffold based viruses
EP16162688.2A EP3184118B1 (en) 2015-12-23 2016-03-29 Recombinant zika vaccines
PCT/EP2016/082659 WO2017109222A1 (en) 2015-12-23 2016-12-23 Recombinant zika vaccines

Publications (1)

Publication Number Publication Date
SG11201804496UA true SG11201804496UA (en) 2018-07-30

Family

ID=55027478

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202004516VA SG10202004516VA (en) 2015-12-23 2016-12-23 Recombinant zika vaccines
SG11201804496UA SG11201804496UA (en) 2015-12-23 2016-12-23 Recombinant zika vaccines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202004516VA SG10202004516VA (en) 2015-12-23 2016-12-23 Recombinant zika vaccines

Country Status (17)

Country Link
US (2) US11110162B2 (en)
EP (5) EP3184119A1 (en)
BR (1) BR112018012962A2 (en)
CY (1) CY1124202T1 (en)
DK (1) DK3393505T3 (en)
ES (1) ES2867954T3 (en)
HR (1) HRP20210591T1 (en)
HU (1) HUE054847T2 (en)
LT (1) LT3393505T (en)
MX (1) MX2018007860A (en)
PL (1) PL3393505T3 (en)
PT (1) PT3393505T (en)
RS (1) RS61939B1 (en)
SG (2) SG10202004516VA (en)
SI (1) SI3393505T1 (en)
WO (2) WO2017109211A1 (en)
ZA (2) ZA201804071B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2937963T3 (en) 2015-07-21 2023-04-03 Modernatx Inc Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. Tropical disease vaccines
BR112018075513A2 (en) 2016-06-13 2019-10-01 Us Health nucleic acids encoding Zika virus-like particles and their use in vaccines and Zika virus diagnostic testing
EP3474892A1 (en) * 2016-06-24 2019-05-01 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
US11434261B2 (en) 2016-07-27 2022-09-06 Hawaii Biotech Inc. Optimized Zika virus envelope gene and expression thereof
GB201613191D0 (en) * 2016-07-29 2016-09-14 Univ Oxford Innovation Ltd Zika virus vaccine
CN109641050A (en) 2016-08-16 2019-04-16 里珍纳龙药品有限公司 Method for being quantified to the individual antibody in mixture
CN109923411B (en) 2016-10-25 2022-05-31 里珍纳龙药品有限公司 Method and system for chromatographic data analysis
MA47515A (en) 2017-02-16 2019-12-25 Modernatx Inc VERY POWERFUL IMMUNOGENIC COMPOSITIONS
EP3412307A1 (en) * 2017-06-07 2018-12-12 Institut Pasteur Recombinant measles virus expressing zika virus proteins and their applications
MA50253A (en) 2017-09-14 2020-07-22 Modernatx Inc ZIKA VIRUS RNA VACCINES
WO2019090228A2 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
CN111601885A (en) 2017-11-30 2020-08-28 武田疫苗股份有限公司 Methods for inactivating Zika virus and related methods
CN107987136A (en) * 2017-12-13 2018-05-04 清华大学 ZIKV-NS1 albumen and its application in zika virus transmission_blocking vaccine is prepared
US11254953B2 (en) 2018-04-18 2022-02-22 Utah State University Compositions and methods for zika virus characterization and vaccine development
EP3581646A1 (en) 2018-06-15 2019-12-18 Themis Bioscience GmbH Integrated manufacturing and chromatographic system for virus production
TW202005694A (en) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 Systems and methods for preparing a polypeptide from a mixture
US20220047691A1 (en) * 2018-10-17 2022-02-17 Texas Tech University System Multivalent Virus Like Particle Vaccines
KR101966841B1 (en) 2018-12-12 2019-04-08 대한민국 Recombinant antigen derived from zika virus e protein and use thereof
EP3673917A1 (en) * 2018-12-28 2020-07-01 Themis Bioscience GmbH Norovirus vaccines
CN109943536B (en) * 2019-03-26 2021-09-14 昆明理工大学 Method for culturing hepatitis E virus and method for preparing inactivated vaccine thereof
WO2020236874A1 (en) * 2019-05-21 2020-11-26 The Regents Of The University Of California Zika virus constructs and therapeutic compositions thereof
WO2021158815A1 (en) * 2020-02-05 2021-08-12 New York Blood Center, Inc. Zika virus immunogenic compositions
CN111875680A (en) * 2020-08-08 2020-11-03 武汉圣润生物科技有限公司 Preparation method and application of novel coronavirus prevention microparticles
EP3957650A1 (en) 2020-08-17 2022-02-23 Themis Bioscience GmbH Co-stimulatory 4-1bbl ectodomain polypeptides for immunomodulation
CN113322282A (en) * 2021-04-20 2021-08-31 华南农业大学 Canine kidney cell line MDCK-pCDH-NS1 for stably expressing NS1 protein and construction method and application thereof
WO2023250054A1 (en) * 2022-06-23 2023-12-28 Merck Sharp & Dohme Llc Immunogenic compositions for epstein-barr virus proteins

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2448971C (en) 2001-06-01 2013-11-26 Acambis, Inc. Chimeric flavivirus vectors
EP1375512B1 (en) 2002-06-20 2009-07-22 Institut Pasteur Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
FR2870126B1 (en) 2004-05-17 2009-07-17 Pasteur Institut RECOMBINANT LENTIVIRAL VECTOR FOR EXPRESSION OF FLAVIVIRIDAE PROTEIN AND ITS APPLICATIONS AS VACCINE
JP2009501520A (en) * 2005-07-14 2009-01-22 メイヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ Paramyxoviridae virus preparation
ATE494906T1 (en) * 2005-11-01 2011-01-15 Novartis Vaccines & Diagnostic CELL-DERIVED VIRAL VACCINES WITH LOW AMOUNTS OF RESIDUAL CELL DNA
EP1939214B1 (en) 2006-12-22 2013-07-10 Institut Pasteur Cells and methodology to generate non-segmented negative-strand RNA viruses
EP3269728B1 (en) * 2011-10-20 2020-12-16 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
ES2648899T3 (en) * 2011-12-09 2018-01-08 Institut Pasteur Multiplex Screening Immunoassay
EP2712871A1 (en) 2012-09-27 2014-04-02 Institut Pasteur Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
US9267114B2 (en) 2012-11-07 2016-02-23 Southern Research Institute Flavivirus envelope protein mutations affecting virion disassembly
WO2016130786A2 (en) * 2015-02-15 2016-08-18 Integral Molecular, Inc. Flaviviridae proteins and virions and methods of use thereof
WO2016145149A1 (en) * 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses

Also Published As

Publication number Publication date
WO2017109211A1 (en) 2017-06-29
HUE054847T2 (en) 2021-10-28
EP3393513A1 (en) 2018-10-31
EP3393505A1 (en) 2018-10-31
MX2018007860A (en) 2018-11-09
DK3393505T3 (en) 2021-05-10
ZA201804071B (en) 2020-01-29
US11110162B2 (en) 2021-09-07
EP3903814A1 (en) 2021-11-03
EP3184118B1 (en) 2020-05-06
WO2017109222A1 (en) 2017-06-29
PT3393505T (en) 2021-04-28
ES2867954T3 (en) 2021-10-21
HRP20210591T1 (en) 2021-05-28
US20190083601A1 (en) 2019-03-21
EP3184118A1 (en) 2017-06-28
SG10202004516VA (en) 2020-06-29
RS61939B1 (en) 2021-07-30
LT3393505T (en) 2021-05-25
ZA201804735B (en) 2019-05-29
EP3184119A1 (en) 2017-06-28
CY1124202T1 (en) 2022-05-27
SI3393505T1 (en) 2021-08-31
US10894079B2 (en) 2021-01-19
PL3393505T3 (en) 2021-10-25
US20180371426A1 (en) 2018-12-27
EP3393513B1 (en) 2021-04-21
EP3393505B1 (en) 2021-03-31
WO2017109211A9 (en) 2017-07-20
BR112018012962A2 (en) 2018-12-04

Similar Documents

Publication Publication Date Title
SG11201804496UA (en) Recombinant zika vaccines
SG11201811432WA (en) Rna for cancer therapy
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201807912SA (en) Vaccine against rsv
SG11201805120YA (en) Zika virus vaccine
SG11201909572QA (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201811603WA (en) Novel adeno-associated virus capsid proteins
SG11201806340YA (en) Zika virus vaccine
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201808750PA (en) T cell receptors
SG11201906392WA (en) Nucleoside-modified rna for inducing an immune response against zika virus
SG11201804729RA (en) Methods and compositions for treating a serpinc1-associated disorder
SG11201808751SA (en) T cell receptors
SG11201806419RA (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
SG11201806845VA (en) Moisturizing compositions and uses thereof
SG11201807051VA (en) Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
SG11201807770RA (en) Sequence arrangements and sequences for neoepitope presentation
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201909353VA (en) Hbv vaccine
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201408153YA (en) Prostate-specific membrane antigen antibody drug conjugates
SG11201407586WA (en) Vaccines for hsv-2
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201909265QA (en) Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to